Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis

Complementary Therapies in Medicine

Volumn 35, Issue , 2017, Pages 6-13

  Daryabeygi Khotbehsara, Reza ^a   Golzarand, Mahdieh ^a   Ghaffari, Mohammad Payam ^b   Djafarian, Kurosh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Fasting blood glucose; Serum lipids; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NIGELLA SATIVA OIL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; PLANT EXTRACT;

BLACK CUMIN; CHOLESTEROL BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLANT SEED; POWDER; REVIEW; SYSTEMATIC REVIEW; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYTOTHERAPY;

BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; MIDDLE AGED; NIGELLA SATIVA; PHYTOTHERAPY; PLANT EXTRACTS; TRIGLYCERIDES;

EID: 85028772689     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2017.08.016     Document Type: Review

References (51)

1. WHO, World Health Organization: Major NCDs and Their Risk Factors; 2017. 2017 http://www.who.int/ncds/introduction/en/.
2. IDF, IDF Diabetes Atlas, seventh edition, International Diabetes Federation. 7th ed., 2015, IDF.
3. Zhang, P., Zhang, X., Brown, J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract, 87(3), 2010, 293.
4. Ikramuddin, S., Korner, J., Lee, W.-J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309:21 (2013), 2240–2249.
5. Rosenstock, J., Vico, M., Wei, L., Salsali, A., List, J.F., Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:7 (2012), 1473–1478.
6. Coppell, K.J., Kataoka, M., Williams, S.M., Chisholm, A.W., Vorgers, S.M., Mann, J.I., Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ, 341, 2010, c3337.
7. Xie, W., Zhao, Y., Zhang, Y., Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid-Based Complement Altern Med, 2011, 2011.
8. Nergiz, C., Ötleş, S., Chemical composition of Nigella sativa L. seeds. Food Chem 48:3 (1993), 259–261.
9. Cheikh-Rouhou, S., Besbes, S., Hentati, B., Blecker, C., Deroanne, C., Attia, H., Nigella sativa L.: Chemical composition and physicochemical characteristics of lipid fraction. Food Chem 101:2 (2007), 673–681.
10. Ahmad, A., Husain, A., Mujeeb, M., et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asia Pac J Trop Biomed 3:5 (2013), 337–352.
11. A-uH, Gilani, Jabeen, Q., Khan, M.A.U., A review of medicinal uses and pharmacological activities of Nigella sativa. Pak J Biol Sci 7:4 (2004), 441–445.
12. Bamosa, A.O., Kaatabi, H., Lebda, F.M., Elq, A.-M.A., Al-Sultan, A., Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol, 54, 2010.
13. Dehkordi, F.R., Kamkhah, A.F., Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol 22:4 (2008), 447–452.
14. Gheita, T.A., Kenawy, S.A., Effectiveness of Nigella sativa oil in the management of rheumatoid arthritis patients: a placebo controlled study. Phytother Res 26:8 (2012), 1246–1248.
15. Kooti, W., Hasanzadeh-Noohi, Z., Sharafi-Ahvazi, N., Asadi-Samani, M., Ashtary-Larky, D., Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin J Nat Med 14:10 (2016), 732–745.
16. El-Hack, M.E.A., Alagawany, M., Farag, M.R., Tiwari, R., Karthik, K., Dhama, K., Nutritional, healthical and therapeutic efficacy of black cumin (Nigella sativa) in animals, poultry and humans. Int J Pharmacol 12 (2016), 232–248.
17. Gholamnezhad, Z., Havakhah, S., Boskabady, M.H., Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol 190 (2016), 372–386.
18. Ijaz, H., Tulain, U.R., Qureshi, J., et al. Nigella sativa (Prophetic medicine): a review. Pak J Pharm Sci, 30(1), 2017.
19. Heshmati, J., Namazi, N., Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med 23:2 (2015), 275–282.
20. Sharma, N., Ahirwar, D., Jhade, D., Gupta, S., Medicinal and phamacological potential of Nigella sativa: a review. Ethnobotanical Leaflets, 2009(7), 2009, 11.
21. Sahebkar, A., Beccuti, G., Simental-Mendía, L.E., Nobili, V., Bo, S., Nigella sativa (black seed) effects on plasma lipid concentrations in humans: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 106 (2016), 37–50.
22. Sahebkar, A., Soranna, D., Liu, X., et al. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. J Hypertens 34:11 (2016), 2127–2135.
23. Mahdavi, R., Heshmati, J., Namazi, N., Effects of black seeds (Nigella sativa) on male infertility: a systematic review. J Herb Med 5:3 (2015), 133–139.
24. Mohtashami, A., Entezari, M.H., Effects of Nigella sativa supplementation on blood parameters and anthropometric indices in adults: a systematic review on clinical trials. J Res Med Sci, 21, 2016.
25. Ahmad, I., Tripathi, J., Sharma, M., Karchulli, M., Umer, L., Nigella sativa – a medicinal herb with immense therapeutic potential (a systematic review). Int J Biol Pharm Res 5:9 (2014), 755–762.
26. ADA. American Diabetes Association, Standards of medical care in diabetes-2016. Diabetes Care, 2016.
27. Alimohammadi, S., Hobbenaghi, R., Javanbakht, J., et al. Protective and antidiabetic effects of extract from Nigella sativa on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation. Diagn Pathol, 8(1), 2013, 818.
28. Kaleem, M., Kirmani, D., Asif, M., Ahmed, Q., Bano, B., Biochemical effects of Nigella sativa L seeds in diabetic rats. Indian J Exp Biol, 44, 2006.
29. Heshmati, J., Namazi, N., Memarzadeh, M.-R., Taghizadeh, M., Kolahdooz, F., Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Food Res Int 70 (2015), 87–93.
30. Moher, D., Shamseer, L., Clarke, M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4(1), 2015, 1.
31. Jadad, A.R., Moore, R.A., Carroll, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17:1 (1996), 1–12.
32. Najmi, A., Nasiruddin, M., Khan, R.A., Haque, S.F., Therapeutic effect of Nigella sativa in patients of poor glycemic control. Asian J Pharm Clin Res 5:Suppl. (3) (2012), 224–228.
33. Hosseini, M.S., Mirkarimi, S.A., Amini, M., Mohtashami, R., Kianbakht, S., Fallah Huseini, H., Effects of Nigella sativa L. seed oil in type II diabetic patients: a randomized, double-blind, placebo – controlled clinical trial. J Med Plants 12:47 (2013), 93–99.
34. Bamosa, A., Kaatabi, H., Badar, A., et al. Nigella sativa: a potential natural protective agent against cardiac dysfunction in patients with type 2 diabetes mellitus. J Fam Community Med 22:2 (2015), 88–95.
35. Hadi, S., Mirmiran, P., Hosseinpour-Niazi, S., Hedayati, M., Azizi, F., Effect of Nigella sativa oil extract on lipid profiles in type 2 diabetic patients: a randomized, double blind, placebo-controlled clinical trial. Iran J Endocrinol Metab 16:6 (2015), 411–418.
36. Heshmati, J., Namazi, N., Memarzadeh, M.R., Taghizadeh, M., Kolahdooz, F., Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Food Res Int 70 (2015), 87–93.
37. Kaatabi, H., Bamosa, A.O., Badar, A., et al. Nigella sativa improves glycemic control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: placebo controlled participant blinded clinical trial. PLoS One, 10(2), 2015.
38. Badar, A., Kaatabi, H., Bamosa, A., et al. Effect of Nigella sativa supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial. Ann Saudi Med, 37(1), 2017 [506].
39. Kanter, M., Meral, I., Yener, Z., Ozbek, H., Demir, H., Partial regeneration/proliferation of the Β-cells in the Islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. Tohoku J Exp Med 201:4 (2003), 213–219.
40. Fararh, K., Atoji, Y., Shimizu, Y., Shiina, T., Nikami, H., Takewaki, T., Mechanisms of the hypoglycaemic and immunopotentiating effects of Nigella sativa L. oil in streptozotocin-induced diabetic hamsters. Res Vet Sci 77:2 (2004), 123–129.
41. Benhaddou-Andaloussi, A., Martineau, L.C., Spoor, D., et al. Antidiabetic activity of Nigella sativa. Seed extract in cultured pancreatic β-cells, skeletal muscle cells, and adipocytes. Pharm Biol 46:1–2 (2008), 96–104.
42. Benhaddou-Andaloussi, A., Martineau, L., Vuong, T., et al. The in vivo antidiabetic activity of Nigella sativa is mediated through activation of the AMPK pathway and increased muscle Glut4 content. Evid-Based Complement Altern Med, 2011, 2011.
43. Fararh, K.M., Ibrahim, A.K., Elsonosy, Y.A., Thymoquinone enhances the activities of enzymes related to energy metabolism in peripheral leukocytes of diabetic rats. Res Vet Sci 88:3 (2010), 400–404.
44. Pari, L., Sankaranarayanan, C., Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin–nicotinamide induced diabetic rats. Life Sci 85:23 (2009), 830–834.
45. Kay, S., Strickson, A., Puelles, J., Selby, R., Benson, E., Tolley, K., Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 diabetes: a systematic review and network meta-Analysis. Diabetes Ther, 2017, 1–23.
46. Kocyigit, Y., Atamer, Y., Uysal, E., The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats. Saudi Med J 30:7 (2009), 893–896.
47. Benhaddou‐Andaloussi, A., Martineau, L., Vallerand, D., et al. Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells. Diabetes Obes Metab 12:2 (2010), 148–157.
48. Meral, I., Yener, Z., Kahraman, T., Mert, N., Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti‐oxidant defence system and liver damage in experimentally‐induced diabetic rabbits. J Vet Med Ser A 48:10 (2001), 593–599.
49. Al-Naqeep, G., Ismail, M., Allaudin, Z., Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by thymoquinone-rich fraction and thymoquinone in HepG2 cells. J Nutrigenet Nutrigenomics 2:4–5 (2009), 163–172.
50. Kannel, W.B., Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 110:5 (1985), 1100–1107.
51. Cholesterol Treatment Trialists C. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:9607 (2017), 117–125.